Core Viewpoint - The company, Jinxin Reproductive Medicine (01951), has announced a share buyback plan, indicating that its current trading price does not reflect its intrinsic value or actual business prospects [1] Group 1: Share Buyback Details - The company is authorized to repurchase up to 274 million shares, which represents 10% of the total shares issued as of the date of the annual general meeting, excluding treasury shares [1] - The board has resolved to utilize the buyback authorization to repurchase shares in the open market for a total price of no less than HKD 100 million [1] Group 2: Rationale and Financial Position - The company believes that the proposed share buyback will demonstrate its confidence in its business development prospects [1] - The existing financial resources of the company are deemed sufficient to support the implementation of the proposed share buyback while maintaining a robust financial position [1]
锦欣生殖拟不少于1亿港元的总价格购回股份